EST
ITOS

EA Series Trust’s iTeos Therapeutics ITOS Stock Holding History

EA Series Trust’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.34M Buy
+101,304
New +$1.44M 0.05% 529

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EA Series Trust's ITOS Position: Q2 2023 in Review

EA Series Trust opened a new position in iTeos Therapeutics (ITOS) in Q2 2023: 101,304 shares worth $1.34M. The stake represents 0.05% of the portfolio and ranks #529 among its holdings.

146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • EA Series Trust held 101,304 shares of iTeos Therapeutics worth $1.34M as of Q2 2023.
  • iTeos Therapeutics was a new EA Series Trust position in Q2 2023.
  • iTeos Therapeutics made up 0.05% of EA Series Trust's portfolio in Q2 2023, its #529 holding.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.